Risks of Gaucher's treatment

被引:3
作者
Barranger, JA [1 ]
机构
[1] Univ Pittsburgh, Ctr Study & Treatment Lysosomal Storage Dis, Pittsburgh, PA 15261 USA
关键词
D O I
10.1016/S0140-6736(05)74261-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1353 / 1354
页数:2
相关论文
共 3 条
[1]   N-butyldeoxygalactonojirimycin:: A more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo [J].
Andersson, U ;
Butters, TD ;
Dwek, RA ;
Platt, FM .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (07) :821-829
[2]  
Cox T, 2000, LANCET, V356, P676, DOI 10.1016/S0140-6736(05)73819-8
[3]   Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis [J].
Cox, T ;
Lachmann, R ;
Hollak, C ;
Aerts, J ;
van Weely, S ;
Hrebícek, M ;
Platt, F ;
Butters, T ;
Dwek, R ;
Moyses, C ;
Gow, I ;
Elstein, D ;
Zimran, A .
LANCET, 2000, 355 (9214) :1481-1485